A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)
ccRCC Post Nephrectomy (Adjuvant Therapy)
University of Malaya Medical Centre (UMMC)
PRINCIPAL INVESTIGATOR
DR MARNIZA SAAD
marniza@ummc.edu.my
CONTACT
SC: Cryst Sari: 03-79492120 (Research Room)
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
DR VOON PEI JYE
voonpj@yahoo.com
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
Facebook
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
DR SOO HOO HWOEI FEN
hwoeifen@yahoo.com
CONTACT
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
Facebook
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (STELLAR 304)
Advnaced Non Clear Celll Renal Cell Carcinoma (NccRCC)
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
DR SUHANA BINTI YUSAK
suhanayusak@gmail.com
CONTACT
General line : 03 – 8892 5555 CRC: 03 – 8892 5555 Ext 5418 (Tel) / 03- 8892 5622 (Fax)
Kuala Lumpur Hospital (HKL)
PRINCIPAL INVESTIGATOR
DR IBTISAM MUHAMAD NOR
maryamsofiyyah@yahoo.com.my
CONTACT
General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel)
crc.hkl@moh.gov.my (email)
Crc Hkl / Clinical Research Centre HKL (Facebook)